Cardiovascular Complications of COVID-19: Risk, Pathogenesis and Outcomes

دانلود کتاب Cardiovascular Complications of COVID-19: Risk, Pathogenesis and Outcomes

52000 تومان موجود

کتاب عوارض قلبی عروقی COVID-19: خطر، پاتوژنز و پیامدها نسخه زبان اصلی

دانلود کتاب عوارض قلبی عروقی COVID-19: خطر، پاتوژنز و پیامدها بعد از پرداخت مقدور خواهد بود
توضیحات کتاب در بخش جزئیات آمده است و می توانید موارد را مشاهده فرمایید


این کتاب نسخه اصلی می باشد و به زبان فارسی نیست.


امتیاز شما به این کتاب (حداقل 1 و حداکثر 5):

امتیاز کاربران به این کتاب:        تعداد رای دهنده ها: 3


توضیحاتی در مورد کتاب Cardiovascular Complications of COVID-19: Risk, Pathogenesis and Outcomes

نام کتاب : Cardiovascular Complications of COVID-19: Risk, Pathogenesis and Outcomes
ویرایش : 1st ed. 2022
عنوان ترجمه شده به فارسی : عوارض قلبی عروقی COVID-19: خطر، پاتوژنز و پیامدها
سری :
نویسندگان :
ناشر : Springer
سال نشر : 2022
تعداد صفحات : 424 [416]
ISBN (شابک) : 3030900649 , 9783030900649
زبان کتاب : English
فرمت کتاب : pdf
حجم کتاب : 13 Mb



بعد از تکمیل فرایند پرداخت لینک دانلود کتاب ارائه خواهد شد. درصورت ثبت نام و ورود به حساب کاربری خود قادر خواهید بود لیست کتاب های خریداری شده را مشاهده فرمایید.

توضیحاتی در مورد کتاب :




این کتاب شواهدی را که در پس رابطه بین COVID-19 و بیماری قلبی بر اساس داده‌های پیشرفته در حال ظهور است، مورد بحث قرار می‌دهد. گسترش سریع و غیرمنتظره جهانی کووید-19 سطوح متناسبی از عوارض قلبی عروقی و متابولیک را آشکار کرده است. مکانیسم های بیماری زایی بی شماری به سطح آمده است. هنوز تحقیقات زیادی مورد نیاز است تا مشخص شود آیا بیماری قلبی عروقی باعث عوارض COVID-19 می شود یا اینکه بیماری قلبی عروقی در نتیجه عفونت ظاهر می شود و کدام مکانیسم ها مسئول آن هستند. با توجه به اینکه بیماری‌های قلبی عروقی و متابولیک در حال حاضر در سطح همه‌گیری قرار دارند و انتظار می‌رود افزایش بیشتری پیدا کنند، این کتاب تجزیه و تحلیل فوری و کامل این ارتباط را در اختیار خوانندگان قرار می‌دهد.

عوارض قلبی عروقی COVID-19: خطر، پاتوژنز و پیامدها به تعداد فزاینده‌ای از سؤالات مربوط به بیماری‌های قلبی در COVID-19 پاسخ می‌دهد و ارتباط بین این همه‌گیری‌ها و شامل عوامل خطر، مکانیسم‌ها و نحوه تأثیرگذاری این موارد بر جمعیت‌های مختلف بیماران را برجسته می‌کند. این توضیح می‌دهد که چگونه COVID-19 بر بیماران مسن‌تر و مبتلایان به بیماری‌های متابولیک مانند چاقی و دیابت تأثیر می‌گذارد، در حالی که یک نمای کلی از دوگانگی جنسیتی مشاهده شده در میان بیماران ارائه می‌دهد. بنابراین نه تنها برای همه پزشکان قلب و عروق بلکه برای هر متخصص مراقبت بهداشتی که بیماران مبتلا به این بیماری‌ها یا کسانی که کووید-19 را بررسی می‌کنند، یک منبع ضروری است.


فهرست مطالب :


Contents 1 The Epidemiology of CoViD19 and Cardiovascular Diseases 1.1 Introduction 1.2 Epidemiology 1.2.1 Cardiovascular Disease or CoViD19, Which Comes First? 1.2.2 The Burden of Cardiovascular Risk Factors in CoViD19 1.2.3 Role of the Pre-existing Cardiovascular Diseases in CoViD19 1.2.4 Critical CoViD19 Complications and Pre-existing Cardiovascular Disease 1.2.5 Role of Cardiovascular Complications in CoViD19 Mortality 1.3 Discussion 1.4 Conclusion References 2 Virology of CoViD19 2.1 Viral Characteristics 2.1.1 Origins of SARS CoV2 2.1.2 Hosts 2.1.3 SARS CoV2 Structure 2.1.4 SARS CoV2 Affinity and Infectivity 2.1.5 SARS CoV2 Variability and Strains 2.2 Mechanism of Viral Entry in Cells 2.2.1 SARS CoV2 Viral Spike-ACE2 Signaling Mechanisms 2.2.2 SARS COV, Cell Entry, and Receptors 2.2.3 SARS CoV2 Similarities with SARS COV and MERS 2.2.4 SARS CoV2, Cell Entry and Receptors 2.3 Summary References 3 An Introduction to the Clinical and Diagnostic Features, and CoViD19 Complications 3.1 Introduction 3.2 Clinical Symptomatology 3.3 Sepsis and Complications of CoViD19 3.4 Important Diagnostic Features 3.4.1 Viral Sampling 3.4.2 Biochemical and Hematological Features 3.4.3 Radiological Features 3.5 Summary References 4 The Pathological Features of CoViD19 Cardiovascular Complications 4.1 Introduction 4.2 Key Features of Cardiovascular Pathology 4.2.1 The Myocardial Injury in CoViD19 4.2.2 Endomyocardial Biopsy and Myocarditis 4.2.3 Endomyocardial Biopsy and Myocarditis with Viral Localization 4.2.4 The Vascular Injury, Microvascular Cardiac Involvement, and Thromboembolic Features 4.2.5 Endothelial Cell Infection and Apoptosis 4.3 Summary References 5 Treatment Options in CoViD19 5.1 Introduction 5.2 Antiviral Agents in CoViD19 5.2.1 Viral Cell Entry Inhibition and Viral Assembly Blockage 5.3 Amino Quinolones in CoViD19 5.3.1 Analysis of Body of Evidence on Amino Quinolones in CoViD19 5.4 Immune-Based Therapies in CoViD19 5.4.1 Immunomodulatory Agents 5.4.2 Convalescent Plasma, and Antibody-Based Therapies 5.5 Potential Anti-inflammatory Mechanisms 5.5.1 NOD-Like Receptor Protein 3 (NLRP3)-Anti-inflammasomes 5.5.2 Neutrophil Extracellular Traps (NETs)-Anti NETosis Therapy 5.6 Anticoagulants 5.7 CoViD19 Vaccines 5.8 Summary References 6 An Introduction to the Pathogenetic Mechanisms of CoViD19 Complications 6.1 Introduction 6.2 Acute Pulmonary Injury 6.3 Sepsis and Multi-organ Failure 6.4 Renin Angiotensin System 6.5 Endothelin System 6.6 Immune-Inflammation 6.7 Summary References 7 Overview of Cytokines and CoViD19 7.1 Introduction 7.2 Cytokines 7.2.1 Interferon 7.2.2 Interleukins 7.2.3 Chemokines 7.2.4 Colony Stimulating Factors 7.2.5 Tumor Necrosis Factor 7.3 Cytokine Storm in CoViD19 7.3.1 Kinetics of the Cytokine Storm 7.3.2 The “T” Cell Response 7.3.3 Cytokines and Severity of CoViD19 7.4 Cytokines in Cardiovascular and Metabolic Diseases 7.5 Summary References 8 The Renin-Angiotensin System in COVID19 8.1 Introduction 8.2 The Renin Angiotensin System 8.2.1 ACE2 Synthesis and Distribution 8.2.2 ACE2 Expression 8.2.3 ACE2 Detection 8.3 The Dynamics of ACE2 Expression in CoViD19 8.3.1 ACE2 Expression in Cardiovascular and Metabolic Conditions 8.3.2 The Dynamics of ACE2 Expression and Cardiovascular Risk in CoViD19 8.3.3 Age and Gender Variations of ACE2 and CoViD19 8.4 ACE2 is a Marker of Severity or a Compensatory Mechanism? 8.5 Summary References 9 Thrombosis in CoViD19 9.1 Epidemiology 9.2 Mechanisms Promoting Thrombosis in CoViD19 9.2.1 Renin Angiotensin System and Thrombosis 9.2.2 Endothelial Cell Damage and Thrombosis 9.2.3 Inflammation and Thrombosis 9.2.4 Microangiopathy and Thrombosis in CoViD19 9.2.5 Platelets and Thrombosis in CoViD19 9.2.6 D Dimers in CoViD19 9.2.7 Hypoxia and Thrombosis 9.2.8 Ethnic Disparities, High-Risk Subgroups and Coagulation 9.3 Summary References 10 Pathogenesis of CoViD19—Miscellaneous Mechanisms 10.1 Introduction 10.2 Regulatory Peptide Systems in CoViD19 10.2.1 Kallikrein-Kinin System 10.2.2 Endothelin System 10.2.3 Natriuretic Peptide System 10.3 Miscellaneous Mechanisms 10.3.1 Direct Viral Damage 10.3.2 Endoplasmic Reticulum Stress 10.3.3 Cell Death Modalities 10.3.4 Mitochondrial Dysfunction 10.4 Summary References 11 Myocardial Injury in CoViD19 11.1 Introduction 11.2 Epidemiology of Myocardial Injury 11.3 Definition, Presentation, and Challenges of Myocardial Injury 11.4 Timing and Assessment of Myocardial Injury 11.5 Biomarkers of Myocardial Injury 11.6 Pathogenesis of the Myocardial Injury 11.7 Summary References 12 Heart Failure in CoViD19 12.1 Epidemiology 12.2 Role of Comorbidities in Heart Failure with CoViD19 12.3 Biomarkers of Heart Failure in CoViD19 12.4 Pathogenetic Mechanisms of Heart Failure in CoViD19 12.5 Summary References 13 Hypertension in CoViD19 13.1 Epidemiology 13.2 Complexities in Hypertension and CoViD19 13.3 CoViD19 Susceptibility and Hypertension 13.4 Pathogenesis 13.5 Summary References 14 Cardiac Arrhythmias in CoViD19 14.1 Epidemiology of Arrhythmias in CoViD19 14.2 Pathogenesis of Arrhythmias in CoViD19 14.3 Summary References 15 Acute Coronary Syndromes in CoViD19 15.1 Epidemiology of Acute Coronary Syndromes in CoViD19 15.2 Defining Acute Coronary Syndromes, Challenges in Presentation and Assessment 15.3 Pathogenesis of Acute Coronary Syndromes in CoViD19 15.4 Summary References 16 Diabetes Mellitus and COVID19 16.1 Epidemiology 16.2 Pathogenesis 16.3 Treatment Implications 16.4 Summary References 17 Obesity and COVID19 17.1 Introduction 17.2 Pathogenetic Links – Obesity and CoViD19 17.3 Summary References 18 The Older Age Adults and COVID19 18.1 Epidemiology 18.1.1 Oder Age and CoViD19 Criticality 18.1.2 CoViD19 Fatality in Older Age Adults 18.1.3 Older Age and Cardiovascular Disease in CoViD19 18.2 CoViD19 Biomarkers in Older Adults 18.3 Risk Mechanisms in Older Age and CoViD19 18.3.1 Immune Dysfunction and Inflammation 18.3.2 ACE2 Mechanisms 18.3.3 Miscellaneous Age Related Mechanisms 18.4 Summary References 19 Gender Disparity in CoViD19 19.1 Epidemiology 19.2 Discrepancies in the Epidemiological Data 19.3 Factors Associated with Gender Dichotomy 19.4 Gender Disparity in Immune Response 19.5 Gender Disparity in ACE2 Mechanisms 19.6 Gender Disparity in Cardiovascular Diseases 19.6.1 Cardiovascular Pathogenetic Features and Gender 19.7 Summary References 20 An Overview of Quality of Research in COVID19 20.1 Introduction 20.2 Quality Issues in CoViD19 Research and Improvement Initiatives 20.3 Summary References Index

توضیحاتی در مورد کتاب به زبان اصلی :


This book discusses the evidence behind the relationship between COVID-19 and heart disease based on emerging state-of-the-art data. The rapid and unexpected global spread of the COVID-19 has revealed proportional levels of cardiovascular and metabolic complications. A myriad of pathogenetic mechanisms has come to the surface. There is still much research required to define whether cardiovascular disease causes COVID-19 complications or that cardiovascular disease appears as a result of the infection and which mechanisms are responsible. With cardiovascular and metabolic diseases already at pandemic levels and expected to increase further, this book provides readers with an urgent and thorough analysis of this association.

Cardiovascular Complications of COVID-19: Risk, Pathogenesis and Outcomes provides answers to the increasing numbers of questions related to heart disease in COVID-19, highlighting the association between these pandemics and including risk factors, mechanisms and how these may impact diverse patients populations. It describes how COVID-19 impacts older patients and those with metabolic illnesses such as obesity and diabetes mellitus, while providing an overview of the observed gender dichotomy among patients. It therefore represents an essential resource not only for all cardiovascular physicians but also for any healthcare professionals managing patients with these diseases or those exploring COVID-19.




پست ها تصادفی